Stifel lowered the firm’s price target on Crispr Therapeutics (CRSP) to $53 from $59 and keeps a Hold rating on the shares following the ...

Financials climbed across the board in anticipation that a new Trump administration will take a friendlier approach to Wall ...

Stifel Nicolaus analyst Tore Svanberg maintained a Sell rating on Alpha and Omega (AOSL – Research Report) today and set a price target ...

Investing.com -- Shares of Barry Callebaut (SIX: BARN) rose following its results, which showed a stronger-than-expected ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, ...

Cornell Belcher, Brilliant Corners Research's founder and president, and Brian Gardner, Stifel's chief Washington policy ...

Shares of Bowlero Corp ( NYSE: BOWL) are building on Monday's after-hours gains and are up 16% from the previous close as the ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

A few days ago, it said it had sold off a small portion of its wealth management business to Stifel Financial Corp. for up to ...

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock sharply ...

Vice President Kamala Harris and former President Donald Trump offer a clear contrast on whether the energy debate in the US ...